In Brief: Medtronic Activa
This article was originally published in The Gray Sheet
Executive Summary
Medtronic Activa: Implantable neurological stimulation device should be approved for use to suppress tremor associated with essential tremor (ET) and Parkinson's disease, FDA's Neurological Devices Panel concludes in 8-0 vote at March 14 meeting in Rockville, Maryland. Clinical data from an eight-site U.S. study and supplemental European clinicals demonstrate that use of the electrical stimulation system results in a statistically significant decrease in tremor activity and is safe and effective for tremor treatment. While all panel members felt that the data submitted in conjunction with the firm's April 1996 premarket approval application supported single implants, the panel was evenly split (4-4) on approval for bilateral implantation due to limited supporting data for that use...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.